CompletedPhase 4NCT00164281
Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centers for Disease Control and Prevention
- Principal Investigator
- Taraz Samandari, MD, PHDCenters for Disease Control and Prevention
- Intervention
- Isoniazid(drug)
- Enrollment
- 2000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2011
Study locations (1)
- Gaborone and Francistown Health Clinics, Gaborone and Francistown, Botswana
Collaborators
Botswana Ministry of Health · United States Agency for International Development (USAID)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00164281 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine